CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 6 enrolled
Drug / intervention
Paclitaxeldrug
Likely dose
Paclitaxel 100 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00971945
NCT00971945Phase 2Completed
CompareCT.gov

Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer

Bristol-Myers Squibb·interventional·Posted Sep 4, 2009·Updated May 25, 2021

In Brief

A Phase 2 clinical trial evaluating Paclitaxel for Breast Cancer. Completed, enrolled 6 participants across 4 sites.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of continued administration of paclitaxel given weekly in subjects considered to need to continue treatment after completion of the preceding "Phase II Clinical Study of Weekly Paclitaxel (BMS-181339) with Advanced Breast Cancer (Protocol No. CA139-371)"

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 4, 2009
Enrollment StartJun 30, 2005
Primary CompletionMar 31, 2008
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 16.8 years ago

Interventions

Paclitaxeldrug

Solution, I.V., 100 mg/m2, Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent